Both Src and a V integrins are important for tumor growth and angiogenesis. They are interconnected and responsible for important features of the tumor phenotype including invasiveness, metastasis, angiogenesis, and resistance to apoptosis. This study examines whether combinational inhibition of both integrin and Src pathways would exert greater antiangiogenesis and antitumor effects than either pathway alone. Using in-vitro cell culture systems, the activity of CNTO95 (Intetumumab), an a V integrin inhibitor, and dasatinib, an Src inhibitor, on proliferation, adhesion, and migration was evaluated in colon cancer cell lines, HCT-116 and RKO, as well as HUVEC cells. The antiangiogenic effect of this combinatory regimen was also tested using an in-vitro tubular network formation assay. The effects of CNTO95 and dasatinib on the activation of Src and integrin pathway signal transduction were also determined by western blotting. The combination of CNTO95 plus dasatinib inhibited adhesion, migration, and paxillin phosphorylation in both HCT-116 and RKO cells. CNTO95 and dasatinib also led to increased apoptosis of HCT-116 cells; however, similar effects were not observed in RKO cells. In addition, dual treatment of CNTO95 and dasatinib exerted enhanced effects on HUVEC cell proliferation, invasion, tubular network formation, and paxillin phosphorylation. In conclusion, our results suggest that concurrent inhibition of both the integrin and the Src pathways exert more pronounced antiangiogenic and antitumor effects than with either pathway being inhibited alone.
Introduction
Integrins are a diverse family of cell-surface heterodimeric proteins that mediate interactions between cells and the extracellular matrix (ECM) as well as cell-cell interactions [1] . Each integrin, consisting of a large a subunit and a smaller b subunit, serves as a receptor for various ECM ligands, soluble ligands, and other cell surface ligands [2] . Integrins and their ligands play key roles in regulating cell survival, proliferation, adhesion, and migration [3] [4] [5] . In addition to mediating cell adhesion, integrins relay molecular cues from the cellular environment to the cytoskeleton through the activation of multiple intracellular signaling pathways [6] . Upon ligand binding, signaling cascades are initiated through the recruitment and activation of Src kinase by phosphorylation of focal adhesion kinase (FAK). The activated FAK-Src complex then activates a series of downstream events that are essential for many physiological and pathological functions of integrins [7] .
The a V integrin subfamily is composed of five receptors: 6 , and a V b 8 [8] . The a V integrins have been implicated in tumor angiogenesis and tumor progression [9, 10] , and integrin overexpression has been observed in various types of human cancers [11] [12] [13] [14] [15] [16] [17] . CNTO95 (Intetumumab) is a fully humanized, monoclonal antibody that binds to and blocks human a V integrins [18] . In preclinical studies, CNTO95 not only showed potent antiangiogenic activity in nude rat models, because of its cross-reactivity with rat integrins [18] , but also inhibited tumor growth and metastasis in both nude rats and nude mice [18, 19] . CNTO95 has been evaluated in several early-phase clinical trials across a range of tumor types. Multiple phase I trials found CNTO95 to be safe and well tolerated in patients with advanced solid tumors [20] [21] [22] . In addition, the combination of dacarbazine plus CNTO95 in stage IV melanoma patients indicated a nonsignificant trend toward improved overall survival [23] .
Src is a small nonreceptor tyrosine kinase that belongs to the Src family kinases [24] . Src family kinases regulate diverse cellular functions including proliferation, migration, cytoskeletal reorganization, and cellular survival by interacting with and/or phosphorylating specific substrates [25] . Src is overexpressed and/or activated in a wide range of tumors including human colon and rectal adenocarcinomas [26] . Notably, colorectal cancers show a progressive increase in Src expression levels and Src activity as the tumor stage advances, suggesting a potential role for Src in assisting tumor progression [27] . Dasatinib is a small-molecule inhibitor of Src kinase activity, but also inhibits other tyrosine kinases such as Abl, c-kit, and PDGFR-b [28] . It has been approved for use in chronic myeloid leukemia, resistant or intolerant to imatinib, and is currently in clinical trials for use in other tumor types [29] .
Because of the upregulation of a V integrins and the activation of Src in colorectal cancer cells, the potential for cooperative or synergistic interactions exists. Importantly, although the activation of Src and a V integrins can occur independently of each other, they later converge to form a stable FAK-Src complex, which is important for cell invasion and metastasis [30] . To explore whether dual inhibition of a V integrins and Src kinase activity could potentially be a more effective antitumor strategy, we examined the effects of CNTO95 and dasatinib on human colon cancer cell proliferation, adhesion, and migration in vitro. In addition, we investigated the proliferation, migration, and tubular formation of human endothelial cells in response to a dual inhibition regimen in vitro as an indication of its antiangiogenic activity. Finally, to better understand the underlying molecular mechanisms of CNTO95 and dasatinib treatment, we further evaluated the downstream signaling events.
Materials and methods

Cell culture
HCT-116 and RKO cells were obtained from the American Type Culture Cell Collection through the Duke Cell Culture Facility. HUVEC cells were purchased from Clonetics through the Duke Cell Culture Facility. Cell lines were passaged for fewer than 6 months. HCT-116 and RKO cell lines were authenticated by the cell bank using short tandem repeat PCR and the HUVEC cell line was characterized in accordance with Clonetics test procedures and sampling plans. All cells were sterile and confirmed to be free of mycoplasma. HCT-116 cells were cultured in McCoy's 5a medium containing 10% FBS, 2 mmol/l L-glutamine, and 1% penicillinstreptomycin. RKO cells were cultured in Eagle's minimum essential medium supplemented with 10% FBS, 1% penicillin-streptomycin, 2 mmol/l L-glutamine, and Eagle's BSS. HUVEC cells were cultured in complete endothelial basal medium-2 from Clonetics supplemented with EGM-2 MV BulletKit (Cat# CC-3162; Lonza Group Ltd, Basel, Switzerland). All cells were maintained at 371C in the presence of 5% CO 2 .
Flow cytometry Integrin staining
Briefly, cells were passaged for 24 h before analysis. Cells were harvested in Versene + 0.1% sodium azide (w/v) and washed with DPBS + 0.1% sodium azide (w/v), resuspended in fluorescence activated cell sorter (FACS) buffer (PBS + 2% BSA + 0.1% sodium azide) at 2.5 Â 10 6 cells/ml. Cells were stained with 15 mg/ml primary antibody for 45 min on ice, washed twice, and then stained with secondary antibody at 10 mg/ml on ice in the dark. Cells were resuspended in 500 ml FACS buffer and analyzed on a FACS Canto (BD Biosciences, San Jose, California, USA) flow cytometer and Flowjo software (Tree Star Inc., Ashland, Oregon, USA).
Cell proliferation and viability: 5 Â 10 6 cells were labeled with 1 mmol/l carboxyfluorescein succinimidyl ester (CFSE, Cat# 65-0850; eBioscience, San Diego, California, USA) and plated onto vitronectin-coated plates (Calbiochem, Rockland, Massachusetts, USA; Cat#681105). Cells were cultured overnight before the addition of CNTO95 or dasatinib, and then grown for 24 h. Cells were harvested with 0.05% trypsin-EDTA and stained with APC-conjugated Annexin V (eBioscience; Cat# 88-8007) and 7-aminoactinomycin D (7AAD) (eBioscience; Cat# 00-6993).
Preparation of cell lysates and western blotting
Tissue culture dishes were coated with 1 mg/ml human vitronectin overnight at 41C and subsequently blocked with 1% BSA for 2 h at room temperature. Cells were then plated and incubated overnight at 371C in the presence of 5% CO 2 . Culture media were removed and replaced with serum-free media containing drug or vehicle for 2 h. The serum-free media were then removed and replaced with complete medium containing drug or vehicle for 20 min. Cell lysates were prepared with a modified RIPA buffer containing 20 mmol/l HEPES, 154 mmol/l NaCl, 2 mmol/l MgCl 2 , 1 mmol/l EDTA, 1 mmol/l EGTA, 1% Triton X-100, proteinase inhibitor cocktail (Roche, Basel, Switzerland; Cat# 04693150001), and phosphatase inhibitor cocktails I and II (Sigma, Buchs SG, Switzerland; Cat# P2850 and P5726). Lysates were centrifuged at 16 000g at 41C to remove unbroken cells, nuclei, and other particulates. Proteins were separated on 4-12% NuPAGE gels and transferred to nitrocellulose membranes for western analysis. Images were acquired and quantified using the Odyssey Infrared Imaging System (LiCor Biosciences, Lincon, Nebraska, USA).
Antibodies
Antibodies used for flow cytometry were mouse immunoglobulin G1 (IgG 1 ) anti-human integrin a V monoclonal antibody (Millipore International, Billerica, Massachusetts, USA; Cat# MAB1953Z), mouse IgG 1 anti-human integrin a V b 3 (CD51/61) monoclonal antibody (Millipore International; Cat# MAB1976Z), mouse IgG 1 anti-human integrin a V b 5 monoclonal antibody (Millipore International; Cat# MAB1961Z), mouse IgG 2a anti-human integrin a V b 6 monoclonal antibody (Millipore International; Cat# MAB2077Z), mouse IgG 1 anti-human integrin b 1 monoclonal antibody (Millipore International; Cat# MAB1951Z), mouse IgG 1 Isotype Control (BD Biosciences; Cat# 557273), mouse IgG 2a Isotype Control (BD Biosciences; Cat# 554126), FITC-conjugated AffiniPure F(ab 0 ) 2 Fragment Goat Anti-Human IgG, Fc g (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA; Cat# 109-096-098), and FITC-conjugated AffiniPure F(ab 0 ) 2 Fragment Goat Anti-Mouse IgG, (H + L) (Jackson ImmunoResearch Laboratories; Cat# 115-096-003). CNTO95 and F105 (human monoclonal antibody, IgG 1 ) isotype controls were generously provided by Janssen Pharmaceutical R&D (Raritan, New Jersey, USA).
Antibodies used for western blotting were anti-total FAK (Cat#3285), anti-phospho-FAK Y397 (Millipore International, MAB1144), anti-phospho-FAK Y576/577 (Cat#3281), anti-phospho-FAK 925 (Cat#3284), antitotal paxillin (Cat#2542), anti-phospho paxillin-Y118 (Cat#2541), anti-total Src (Cat#2108), anti-phospho Src Y416 (Cat#2113), and anti-b actin (Sigma; Cat# A5441). The above antibodies were purchased from Cell Signaling Technology (Danvers, Massachusetts, USA), except when noted otherwise. Secondary antibodies included Goat anti-rabbit 680 (Invitrogen, Calsbad, California, USA; Cat#A21109), Goat anti-mouse 680 (Invitrogen; Cat#A21058), and Goat anti-mouse 800 (VWR International LLC, West Chester, Pennsylvania, USA; Cat#610-132-121).
Cell viability assay
Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays from Promega (Madison, Wisconsin, USA) according to the manufacturer's instructions. Briefly, cells were plated in triplicate in 96-well plates coated with vitronectin and blocked with BSA at a density of 50 000 cells per well. Cells were incubated for 16 h before the addition of CNTO95 or dasatinib, and then allowed to grow for 24 h. The MTS substrate was added and the OD490 was determined 2 h later.
Cell adhesion assay
Cells were washed with PBS, incubated in CellStripper (Cellgro, Manassas, Virginia, USA), and resuspended in media. Excess Cellstripper was removed by brief centrifugation (1000g for 5 min). HCT-116 (40 000 cells/ well) or RKO (50 000 cells/well) cells were dispensed into 96-well plates coated with vitronectin (5 mg/ml) and allowed to adhere overnight. The following day, cells were treated for 4 h with the indicated amounts of CNTO95 in the absence or presence of 10 nmol/l dasatinib. Nonadherent cells were removed; the remaining cells were then fixed and stained with crystal violet. Crystal violet was eluted with methanol and adherent cells were quantified at 550 nm. After background subtraction, data points were normalized to DMSO (control)-treated wells and plotted as percent control.
Focal adhesion staining
Cells (15 000/coverslip) were plated on coverslips coated with 5 mg/ml vitronectin and fixed 48 h later in 4% paraformaldehyde. The cells were permeabilized with 0.1% Triton X-100 and incubated with an antivinculin monoclonal antibody (Sigma), followed by incubation with a Cy3-conjugated anti-mouse secondary antibody (Jackson ImmunoResearch Laboratories). The coverslips were washed and affixed to slides with mounting media containing DAPI (Molecular Probes, Eugene, Oregon, USA) to visualize nuclei. Images were obtained using a Zeiss Axio Imager fluorescence microscope equipped with a digital camera and Metamorph software (Molecular Devices, Sunnyvale, California, USA).
Cell migration assays
Cell invasion and migration assays were performed using the BD Biocoat Angiogenesis System (BD Bioscience) according to the manufacturer's protocol. Briefly, 2.5 Â 10 4 cells were added to the top chamber, HUVECs were incubated for 15 h at 371C, whereas cancer cells were incubated for 24 h at 371C. In both cases, at the end of the incubation period, the top chambers were transferred to the PBS-containing wells. The inserts were processed by wiping out cells from the inside of the top chamber using cotton swabs. The cells on the outer surface of the insert were stained using the three-step stain set (Richard-Allen Scientific, Kalamazoo, Michigan, USA). The inserts were removed from the frame and mounted under a cover slide with Cytoseal-60 (Richard-Allen Scientific). The cells occupying a strip were visualized using a Nikon microscope (Â 200 magnification; Nikon Metrology Inc., Brighton, Michigan, USA) and counted. The counts obtained in randomly selected two perpendicular diameters were averaged.
HUVEC tubular network formation
HUVEC were pretreated with CNTO95, dasatinib, or both drugs for 8 h. The cells were harvested and maintained in drug-containing medium, and 1.5 Â 10 4 HUVEC were inoculated onto a prepolymerized ECMatrix gel (in-vitro angiogenesis assay kit; Chemicon, Temecula, California, USA). After an overnight incubation, cells were visualized using an Axio Observer microscope (Carl Zeiss Microscopy Ltd, Cambridge, UK) at the Duke University Light Microscopy Core Facility. Closed polygons were counted; the total number of tubes and the total tube length were measured using MetaMorph software.
Software and statistical analysis
Flow cytometry data were analyzed using Flowjo 8.8.6 (Tree Star Inc.). Western data were analyzed using the Odyssey 3.0 system (LiCor Biosciences). Graphs were generated using Prism 5 software (GraphPad Software Inc, La Jolla, California, USA). The statistical differences between the single-agent treatment and the control were evaluated using Student's t-test. The statistical differences between the combinatorial treatments compared with single-agent treatments were evaluated by one-way analysis of variance, followed by Bonferroni's multiplecomparison tests.
Results
Multiple colon cancer cell lines were initially tested for sensitivity to CNTO95-induced growth inhibition, as determined by MTS assays. Cell lines showing greater than 15% growth inhibition at 1 mg/ml CNTO95 were designated as sensitive cell lines (HCT-116, HCT15, SW48, SW403, and DLD-1), and cell lines showing less than 15% growth inhibition at 1 mg/ml CNTO95 were designated as resistant cell lines (RKO, WiDr, Colo320, SW1417, SW1463, and HT-29). When compared, the sensitive versus the resistant groups were found to be significantly different from one another (unpaired t-test; P = 0.0148). Of all the cell lines tested, HCT-116 cells were the most sensitive to CNTO95 (46.0% growth inhibition), whereas RKO cells were among the most resistant to CNTO95 (10.9% growth inhibition). In addition, both cell lines showed good growth characteristics in vitro. For those reasons, HCT-116 and RKO cell lines were chosen as representative 'sensitive' and 'resistant' cell lines to next explore the effect(s) of combining CNTO95 and dasatinib across a spectrum of cellular and molecular readouts.
Human colon cancer cell lines express multiple a V integrins
The expression patterns of a V integrins on HCT-116 and RKO cells were determined by flow cytometry and expression levels were assessed by the mean fluorescence intensity. As shown in Fig. 1 , the level of a V expression in HCT-116 cells is almost five-fold greater than that observed in RKO cells. In particular, a V b 5 expression was two times greater in HCT-116 cells compared with RKO cells. Also, a V b 6 expression was readily detectable in HCT-116 cells, whereas RKO cells were essentially negative for a V b 6 staining. Neither HCT-116 nor RKO cells expressed a V b 3 . Little or no b 1 expression was observed in either cell type, indicating that a V b 1 integrins were not expressed to appreciable levels in these cells. HCT-116 and RKO cells were positively stained by CNTO95, but not the isotype control, confirming the specific binding of CNTO95 to these cells through a V integrins. Consistent with the a V integrin expression pattern, CNTO95 staining on HCT-116 cells was three fold greater than that observed on RKO cells.
Combination of CNTO95 and dasatinib on cell viability of human colon cancer cell lines
The combinatorial effect(s) of CNTO95 and dasatinib on the growth of HCT-116 cells and RKO cells was determined using MTS assays. Dasatinib treatment (24 h) of HCT-116 cells led to a dose-dependent decrease in viability, with the maximum inhibition reached at 25 nmol/l ( Fig. 2a ). CNTO95 (10 mg/ml; 24 h) alone reduced the number of viable HCT-116 cells by about 20%. The addition of CNTO95 to dasatinibtreated HCT-116 cells led to an additional 10-20% inhibition compared with dasatinib alone (Fig. 2a ). In contrast, RKO cells showed little or no change in overall viability after exposure to either 10 mg/ml CNTO95 or various doses of dasatinib for 24 h (Fig. 2b) . Dasatinib is known to inhibit multiple tyrosine kinases at nanomolar concentrations; however, even when exposed to 200 nmol/l of dasatinib, RKO cell viability was unaffected.
Although MTS assays measure overall cell viability, we aimed to differentiate between cell death and cell proliferation, both of which contribute toward the amount of viable cells. To separate the effects of CNTO95 with or without dasatinib on these two cellular aspects, we tracked cell proliferation using CFSE stains and measured cell death using Annexin V and 7AAD stains by flow cytometry. The intensity of CFSE fluorescence did not change significantly upon drug treatment in either HCT-116 or RKO cells ( Fig. 2c ), suggesting that the proliferation of both cell types was unaffected by CNTO95 and dasatinib, alone or in combination. Next, we evaluated cell death by quantifying the percentage of annexin V-positive cells (apoptotic) and 7AAD-positive cells (necrotic) in both cell types. In contrast to RKO cells, apoptotic and necrotic cell deaths were markedly increased in HCT-116 cells treated either with drug alone or in combination ( Fig. 2e-h ). The combination of both drugs induced more cell death than either drug alone in HCT-116 cells (Fig. 2f ). It appears that both CNTO95 and dasatinib, either as single agents or in combination, limit the expansion of HCT-116 cells in vitro primarily by inducing apoptotic and necrotic cell death, and yet have little effect on proliferation. In contrast, the proliferation and survival of RKO cells remain largely unaffected by these agents.
Combination of CNTO95 and dasatinib on seruminduced migration of human colon cancer cell lines
Cell migration is a critical process mediating tumor metastasis. CNTO95 is able to block a V integrins, which disrupts the connection between the a V integrins and their ECM ligands, thereby affecting tumor cell migration and metastasis. The effect of CNTO95 and dasatinib on the migration of HCT-116 cells and RKO cell was examined. As shown in Fig. 3 , the ability of HCT-116 cells to migrate toward serum was considerably impaired by either CNTO95 (Fig. 3a) or dasatinib (Fig. 3b ) in a dose-dependent manner. The migration of HCT-116 cells was reduced almost 50% by either 10 ng/ml CNTO95 or 5 nmol/l dasatinib ( Fig. 3a and b ). In comparison with either agent alone, the combination of 30 ng/ml CNTO95 and 5 nmol/l dasatinib almost abolished HCT-116 cell migration (Fig. 3c ). However, much higher concentrations of CNTO95 and dasatinib were required to inhibit serum-induced migration of RKO cells ( Fig. 3d and e ). Even at doses as high as 3000 ng/ml CNTO95 or 100 nmol/l dasatinib, RKO cells still retained 30-50% migration ( Fig. 3d and e ). It should be noted that at these higher doses, the combination of dasatinib and CNTO95 did inhibit RKO migration more than either drug alone.
These results suggest that alternative mechanisms may support the migratory activity of RKO cells. Overall, our findings show that the migration of HCT-116 cells is sensitive to both CNTO95 and dasatinib, whereas RKO cells are more resistant. In addition, the migration of both HCT-116 and RKO cells is inhibited more by the combination of both drugs than by either drug alone.
Combination of CNTO95 and dasatinib on adhesion of human colon cancer cell lines a V integrins are known receptors for ECM proteins such as vitronectin and fibronectin. We tested the ability of CNTO95 to inhibit cell binding to vitronectin and whether this effect could be augmented by dasatinib.
The adhesion of both HCT-116 cells and RKO cells was considerably disrupted by CNTO95 in a dose-dependent manner and the addition of 10 nmol/l dasatinib further reduced the number of adhered cells ( Fig. 4a and b ). CNTO95 (0.1 mg/ml) alone inhibited HCT-116 adhesion to vitronectin by 25%, and the addition of 10 nmol/l dasatinib augmented this effect, yielding only 50% adherent cells (Fig. 4a ). The adhesion of RKO cells to vitronectin was reduced by 50% upon treatment with 0.1 mg/ml of CNTO95. The addition of dasatinib further decreased the number of adherent cells to about 15% (Fig. 4b ).
Our observation that the adhesion of RKO cells was more easily disrupted than that of HCT-116 cells led us to postulate that the quantity and/or the size of the focal adhesions are intrinsically different between the two cell lines. Indeed, vinculin staining showed that HCT-116 cells not only had more focal adhesions but that these focal adhesions were also intrinsically larger in size compared with the focal adhesions in the RKO cells ( Fig. 4c and d ).
Combination of CNTO95 and dasatinib inhibits the phosphorylation of FAK, paxillin, and Src induced by serum stimulation in human colon cancer cells
Integrin engagement induces the autophosphorylation of the nonreceptor tyrosine kinase FAK at Y397, creating a high-affinity binding site for Src. Once bound, Src undergoes conformation changes, facilitating additional trans-phosphorylation of FAK at Y576, Y577, and Y925 by Src. The fully activated FAK-Src complex is required for the maximal activation of many substrates, including the downstream kinase, paxillin. The environmental cues are sensed by integrins, transduced by FAK and Src, and lead to eventual changes in cell mobility [31] .
To better understand the signaling mechanism(s) affected by CNTO95 and dasatinib, we examined the effects of these agents on the phosphorylation status of FAK, Src, and paxillin upon serum stimulation. As expected, dasatinib treatment of HCT-116 and RKO cells inhibited serum-induced Src phosphorylation (Fig. 5a and c) . In addition, dasatinib also reduced FAK phosphorylation at Y576/577 and Y925 in both cell lines, but the autophosphorylation site Y397 was largely unaffected. In contrast to dasatinib, CNTO95 treatment alone appeared to have little or no effect on the activation of FAK or Src; however, paxillin phosphorylation was inhibited in both HCT-116 and RKO cells (Fig. 5a and c) . The phosphorylation of paxillin was inhibited more by combining CNTO95 and dasatinib ( Fig. 5b and d ) than using either drug alone, suggesting that paxillin may act as a molecular integrator that accounts for cell survival, adhesion, and migration.
Combination of CNTO95 and dasatinib inhibits HUVEC proliferation, migration, and integrin signal transduction
Integrins are the principal adhesion receptors used by endothelial cells to interact with their extracellular environment [9] . a V b 3 and a V b 5 are critical during tumor angiogenesis [32] , and studies have shown that anti-a V antagonists show clear antiangiogenic activity [18, 33] . To further investigate the effects of CNTO95 and dasatinib on endothelial cells, we used HUVEC cells as a model system. Dasatinib inhibited HUVEC cell viability in a dose-dependent manner. CNTO95 (10 mg/ ml) reduced viable HUVEC cells by about 20%, but the combination of CNTO95 and dasatinib induced a much greater effect on HUVEC viability in comparison with either treatment alone at the doses tested (Fig. 6a ).
Individually, CNTO95 and dasatinib were able to inhibit serum-induced migration of HUVEC cells, but when combined together, more pronounced inhibition of HUVEC migration was observed (Fig. 6b ). In fact, 10 mg/ml of CNTO95 plus 100 nmol/l dasatinib almost completely blocked the migration of HUVEC cells. Taken together, these results suggest that the combination of CNTO95 and dasatinib may affect tumor angiogenesis in addition to direct effects on tumor cells.
Finally, protein lysates were extracted from drug-treated HUVEC cells after serum stimulation to examine the phosphorylation status of FAK, paxillin, and Src. Although the overall signal was low, the phosphorylation of Src was reduced in the presence of dasatinib, as was the phosphorylation of FAK at Y576/577 and Y925, presumably because of the significant decrease in Src activity. Similar to our observations above using colon cancer cells, paxillin phosphorylation was also reduced, most likely as a result of compromised FAK and Src activation. CNTO95 alone had very little effect on the phosphorylation of FAK, Src, and paxillin (Fig. 6c ). However, when CNTO95 was combined with dasatinib, increased inhibition of paxillin phosphorylation was observed (Fig. 6d) . Although not as pronounced, this effect was observed in both endothelial cells and colon cancer cells, suggesting that the CNTO95 and dasatinib combination may impact both the tumor directly as well as the supporting vasculature.
The combination of CNTO95 and dasatinib inhibits HUVEC tubular network formation
Capillary tube formation is an essential event during angiogenesis. It is a multistep process involving endothelial cell adhesion, migration, differentiation, and proliferation [34] . To test the effects of CNTO95 and dasatinib on angiogenesis, we utilized an in-vitro 2D ECM gel system to examine HUVEC tube formation. The inhibitory effect of CNTO95 and dasatinib on HUVEC tubular network formation can be directly visualized under a microscope (Fig. 7d ). For analysis, we could quantify multiple endpoints, including the number of closed polygons, the number of tubes, and the total length of tubes. When HUVECs were treated with 10 mg/ml CNTO95 or 25 nmol/l dasatinib alone, a 10-20 and 37-55% reduction, respectively, in tubular network formation was observed. In addition, the combination of CNTO95 and dasatinib induced more profound inhibition on angiogenesis, as evidenced by a 50-65% reduction in tube formation (Fig. 7a-c) . Compared with HUVECs treated with either drug alone, the number of tubes and the total length of tubes were significantly lower in cells treated with the combination of both CNTO95 and dasatinib ( Fig. 7b and c) . The combination regimen also led to significantly fewer polygons than CNTO95 treatment alone. A nonsignificant trend was noted for less polygon formation in comparison with dasatinib treatment alone (Fig. 7a ). Overall, our data indicate that both CNTO95 and dasatinib blocked endothelial cell tubular network formation, whereas the combination of both drugs led to a more profound inhibition.
Discussion
Anticancer therapeutics targeting a V integrins have been under active development over the recent years. Among them, CNTO95 and etaracizumab are monoclonal antibodies against a V b 3 and a V b 5 [35] . Others include cilengitide [36] , a synthetic peptide containing the RGD sequence, peptidomimetics S137 and S247 [37] , as well as a nonpeptide antagonist PSK1404 [38] . CNTO95 and cilengitide are the front-runners that have moved to various phases of clinical trials, whereas S137, S247, and PSK1404 currently remain in preclinical development. Previously, some work has been carried out to examine the potential for CNTO95 to be a part of a combinational anticancer regimen. It has been found that CNTO95 potentiates the efficacy of fractionated radiation therapy in mouse xenograft tumor models [39] . Further, a phase I study in patients with castrate-resistant metastatic prostate cancer found that CNTO95 in combination with docetaxel and prednisone was generally safe and well tolerated [21] . The safety and efficacy of CNTO95 in combination with dacarbazine was also evaluated in a randomized phase II trial in stage IV melanoma [23] . Our study is the first to date showing that dual inhibition of a V integrins and Src kinase activity results in profound inhibition of cell survival, adhesion, migration, and integrin signal transduction of both human colon cancer cells and endothelial cells in vitro. The inhibitory effects conferred by CNTO95 and dasatinib as a combination regimen were greater than by either drug alone, implicating CNTO95 and dasatinib as a potential promising combined targeted therapy that exerts both antitumor and antiangiogenic effects.
The expression and function of integrins in endothelial cells are well understood. In contrast, integrin expression in colon cancer cell lines has not been characterized extensively. It has been shown that RKO cells express a 6 b 1 and a 2 b 1 , but not a 6 b 4 [40] . However, little is known about the a V expression profile of RKO cells. Our data not only showed the presence of a V integrins but also analyzed the expression pattern of various a V integrins on the surface of RKO cells in comparison with HCT-116 cells. In agreement with a previous study [41] , we found that HCT-116 cells express a V b 5 , but not a V b 3 . We also found that a V b 6 was expressed on HCT-116 cells. In our analysis, neither RKO cells nor HCT-116 cells showed discernible levels of b 1 expression, which had been shown previously to be positive on HCT-116 cells [41] . This discrepancy could be explained by the specificity of the antibodies used. Nonetheless, the characterization a V integrin expression provided a structural basis to better understand the effects of CNTO95 on the two colon cancer cell lines evaluated here.
In an effort to address whether the sensitivity or resistance to CNTO95 is determined by any genetic differences, we adopted the bioinformatics approach to examine integrin pathway components for differential expression patterns across the 11 cell lines tested initially. Except for the WiDr cell line, data on the other 10 cell lines are available in the Novartis/Broad CCLE public database for expression values (U133 + 2; Affymetrix, Santa Clara, California, USA). The average FAK expression from four unique probes is significantly higher in the resistant cell lines (P = 0.027, data not shown). However, no statistical differences were found in a V , b 3 , b 5 , b 6 , Src, or paxillin expression between the sensitive and the resistant groups. The expressions of focal adhesion linker proteins, including vinculin, talin, and zyxin, and the focal adhesion disassembly protease calpain were also examined; no significant differences were observed across the sensitive and resistant cell types (data not shown). These findings from our bioinformatics study suggested that sensitivity to CNTO95 treatment might be determined by the activation status of signaling proteins rather than the quantitative differences in members of the integrin pathway.
CNTO95 and dasatinib exerted more pronounced effects on the inhibition of cell proliferation and migration of HCT-116 cells compared with RKO cells. In support of these findings, a recent study has shown that a V b 3 integrin and c-Src can work together as an oncogenic unit to promote anchorage-independent cell growth and metastasis of pancreatic tumor cells [42] . The viability of RKO cells, however, was not affected by CNTO95 and dasatinib either as single agents or in combination.
Our results also show that the migration of RKO cells is resistant to CNTO95 and dasatinib treatment. Low concentrations of CNTO95 and dasatinib were sufficient to inhibit cell migration in HCT-116, whereas 20-fold higher concentrations were required to achieve a comparable degree of inhibition in RKO cells. These findings indicate that individual human colon cancer cell lines show differential dependence on a V integrin and Src kinase activity for their survival and migration. The differing sensitivities to CNTO95 between the two cell lines may be, in part, explained by the quantitative differences in their a V integrin expression, which leads to differential binding affinity for CNTO95 to unique cell types and subsequent signaling activation. Interestingly, further examination of the integrin signaling pathways showed that signaling in HCT-116 and RKO cells was perturbed to a similar extent by CNTO 95 and dasatinib, despite the drastic differences in their proliferation and migration behavior upon drug treatment. It is known that integrin activation induces extensive crosstalk between multiple pathways through a complex signaling network [43] . For example, engagement of integrins induces transactivation of growth factor receptors, such as PDGFR and EGFR [44] . Other signaling pathways that can be activated by integrins include the MAPK pathway, the PI3/Akt pathway, the NF-kB pathway, as well as small GTPases [45] . These intersecting signaling cascades work in coordination to regulate cell proliferation, adhesion, and migration. Therefore, a more thorough examination of multiple signaling pathways may be required to help identify key signal transduction points underlying the differential responses to CNTO95.
CNTO95 and dasatinib are effective in decreasing the adhesion of both HCT-116 and RKO cells. Focal adhesion complex formation and focal adhesion disassembly/ turnover are two distinct, yet carefully orchestrated processes that mediate cell adhesion and migration. The differences in the expression of the key components involved in these two processes may be responsible for the different responses to CNTO95 and dasatinib in adhesion versus migration. A preliminary bioinformatics analysis using Novartis/ Broad CCLE public database showed a higher RNA expression of FAK and zyxin, and lower RNA expression of talin and calpain in RKO cells than in HCT-116 cells (data not shown). However, this analysis needs further validation of protein expression.
FAK undergoes autophosphorylation at Y397 upon integrin clustering-mediated cell adhesion. Recently, Chen et al. [19] reported the ocurrence of CNTO95 treatmentinduced time-dependent dephosphorylation at the Y397 site in breast cancer cells. However, in our system, phosphorylation of Y397 seemed to be unaffected by CNTO95. It should be noted that our analysis is different from the work of Chen et al. [19] in several ways: (a) we evaluated colon cancer and endothelial cells, whereas their experiments were conducted in breast cancer cells; (b) we measured the effect of drug treatment on Y397 phosphorylation upon serum stimulation, whereas they examined changes in the level of Y397 phosphorylation under serum-free conditions; and (c) in our system, drug exposure was concurrent with starvation, whereas in their system, drug treatment was not initiated until cells had been starved for 2 h in a serum-free medium. Therefore, the discrepancy in the effect of CNTO95 on Y397 phosphorylation status could be because of the intrinsic differences in cell lines, the effect of serum stimulation, or the timing of drug treatment relative to cell starvation. It should be noted that the phosphorylation of two additional downstream sites, Y576 and Y925, was not significantly inhibited by CNTO95 treatment in our analysis. Moreover, the phosphorylation profile of FAK Y397, Y576, and Y925 remained consistent in HCT-116 and RKO cells, as well as in HUVEC cells, showing the overall consistency within our experimental system. We also verified the specificity of all three FAK antibodies FAK Y397, Y576, and Y925 by pervanadate (to induce phosphorylation) or phosphatase (to induce dephosphorylation) treatment of cell lysates (data not shown). All phospho-FAK antibodies tested in our analysis were selective for each phospho-specific site. Nonetheless, the fact that CNTO95 could inhibit cell proliferation, adhesion, and migration on its own clearly indicated its biological activity.
Our analysis of integrin signaling supports the view that paxillin is a potential cellular integrator of a V integrins and Src. Dual inhibition of a V integrins and Src reduced paxillin activation more than either agent alone. This result is consistent with the notion that both Src and FAK activity are required for the maximum activation of paxillin [46] . Paxillin has been recognized as an important adaptor protein, facilitating the interactions between proteins within the focal adhesion complex, thus playing a central role in the signal transduction of integrins upon their engagement by ECM ligands [47] . In our system, inhibition of paxillin activity correlated closely with inhibition on cell adhesion and migration. We postulate that paxillin could act as a molecular focus that integrates the combined inhibitory effects observed with CNTO95 and dasatinib.
Conclusion
Our study shows the combined inhibitory effect of CNTO95 and dasatinib in both colon cancer and endothelial cells in vitro, suggesting additive/synergistic antitumor activity in vivo, where both host endothelial cells and neoplastic epithelial cells contribute toward tumor growth and metastasis.
